A pharma formulation unit manufactures 50 SKUs across 12 therapeutic categories. Production data says 8,400 units left the line last month. Sales invoices show 7,900 units shipped. The difference—500 units—sits recorded as finished goods. Nobody knows which batches, why they were held, or when they will move.
The cash tied to those 500 units (₹4–6 lakhs, typically) is invisible in working-capital forecasts. This reconciliation gap is common in mid-sized pharma and chemical manufacturers. It compounds across quarters and locks liquidity that could fund growth or cover seasonal dips. This article shows how to diagnose the leak, build a batch-to-dispatch reconciliation protocol, and measure the cost.
Advisory
In most pharma units, goods issued from QA (Form 6 or equivalent warehouse stock record) do not match invoiced sales within the same period. The gap—typically 4–8% of monthly output—accumulates in 'in-transit', 'hold pending approval', 'rework', or 'distributor return' buckets that are logged in different systems (ERP, ledger, sales pipeline) without a single source of truth. This fragmentation means a ₹50-lakh monthly production run may carry ₹2–4 lakhs of 'invisible' inventory. The promoter sees revenue recognised but cannot pinpoint why stock reconciliation differs from physical count or why cash from that shipment hasn't arrived. Root causes include: batches held for stability-test data (pharma-specific, regulatory), distributor on-hold (pending indent), rework batches (failed dissolution, assay drift), and invoicing delays (credit terms, pending GST documentation). Quantifying each category is the first step; most units guess or accept the variance as 'normal'.
Unreconciled batch inventory ties up working capital at a cost of 18–24% per annum (the cost of short-term credit for pharma SMEs). A unit with ₹50 lakhs monthly revenue and a 6% untracked inventory gap carries ₹3 lakhs in dead stock. At 20% cost of capital, that costs ₹600/month in buried finance charges—₹7,200/year. Across 12 months, if the gap persists, the unit has paid interest on money it already earned but cannot access. Second-order consequence: the accountant's bank-reconciliation and inventory-audit reports show mismatches that auditors flag as 'internal controls weakness'; lenders scrutinise the variance during credit appraisal (especially under GST, where batch-wise inventory records are now mandatory for HSN classification and ITC matching). A working-capital loan may be sanctioned at 1–2% lower rate if reconciliation is tight; a sloppy audit costs 50–100 bps.
The operating solution is a batch-to-dispatch waterfall: every batch released from QA receives a batch code (already mandatory under Schedule M GMP rules for pharma; Schedule 2 for chemicals under MSDS). That code must be entered into the ERP/MIS at three gates: (1) QA release date, (2) warehouse bin assignment (with hold reason if not immediately invoiced), (3) invoice date/dispatch date. Weekly, the operations or account-management team reconciles gate 1 vs. gate 3 in a simple spreadsheet: batches released 7+ days ago should be either (a) invoiced and dispatched, (b) explicitly on hold with a
Frequently asked questions
Batch reconciliation matches production output (units leaving QA) against invoiced sales to identify inventory gaps held in transit, rework, or approval buckets. This reveals cash trapped in finished goods that doesn't appear in working-capital forecasts.
Mid-sized pharma units typically lock ₹2–5 lakhs per ₹50-lakh monthly production run due to reconciliation gaps. These gaps accumulate across quarters and represent 5–8% of monthly output trapped as invisible inventory.
Common causes include batches on hold for stability-test data, distributor on-holds pending orders, rework batches (failed quality tests), and invoicing delays due to credit terms or GST documentation—each logged in separate systems without a single source of truth.